The prognostic significance of chemotherapy for stage IV gastric cancer patients: A single-institution experience

Toshiro Okuyama, Daisuke Korenaga, Kenichi Koushi, Shinji Itoh, Hirofumi Kawanaka, Yasuharu Ikeda, Kenji Takenaka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined. Methods: This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989-1998), the 2nd (1999-2002), and the 3rd term (2003-2005). Results: There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01). Conclusions: These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.

Original languageEnglish
Pages (from-to)935-940
Number of pages6
JournalSurgery today
Volume41
Issue number7
DOIs
Publication statusPublished - Jul 1 2011
Externally publishedYes

Fingerprint

Stomach Neoplasms
Drug Therapy
Survival
Pharmaceutical Preparations
Residual Neoplasm
Stomach
Multivariate Analysis
Carcinoma

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

The prognostic significance of chemotherapy for stage IV gastric cancer patients : A single-institution experience. / Okuyama, Toshiro; Korenaga, Daisuke; Koushi, Kenichi; Itoh, Shinji; Kawanaka, Hirofumi; Ikeda, Yasuharu; Takenaka, Kenji.

In: Surgery today, Vol. 41, No. 7, 01.07.2011, p. 935-940.

Research output: Contribution to journalArticle

Okuyama, Toshiro ; Korenaga, Daisuke ; Koushi, Kenichi ; Itoh, Shinji ; Kawanaka, Hirofumi ; Ikeda, Yasuharu ; Takenaka, Kenji. / The prognostic significance of chemotherapy for stage IV gastric cancer patients : A single-institution experience. In: Surgery today. 2011 ; Vol. 41, No. 7. pp. 935-940.
@article{5c6858407bfe44c8945f295837009b2c,
title = "The prognostic significance of chemotherapy for stage IV gastric cancer patients: A single-institution experience",
abstract = "Purpose: The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined. Methods: This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989-1998), the 2nd (1999-2002), and the 3rd term (2003-2005). Results: There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01). Conclusions: These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.",
author = "Toshiro Okuyama and Daisuke Korenaga and Kenichi Koushi and Shinji Itoh and Hirofumi Kawanaka and Yasuharu Ikeda and Kenji Takenaka",
year = "2011",
month = "7",
day = "1",
doi = "10.1007/s00595-010-4403-0",
language = "English",
volume = "41",
pages = "935--940",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "7",

}

TY - JOUR

T1 - The prognostic significance of chemotherapy for stage IV gastric cancer patients

T2 - A single-institution experience

AU - Okuyama, Toshiro

AU - Korenaga, Daisuke

AU - Koushi, Kenichi

AU - Itoh, Shinji

AU - Kawanaka, Hirofumi

AU - Ikeda, Yasuharu

AU - Takenaka, Kenji

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Purpose: The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined. Methods: This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989-1998), the 2nd (1999-2002), and the 3rd term (2003-2005). Results: There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01). Conclusions: These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.

AB - Purpose: The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined. Methods: This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989-1998), the 2nd (1999-2002), and the 3rd term (2003-2005). Results: There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01). Conclusions: These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.

UR - http://www.scopus.com/inward/record.url?scp=79960303510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960303510&partnerID=8YFLogxK

U2 - 10.1007/s00595-010-4403-0

DO - 10.1007/s00595-010-4403-0

M3 - Article

C2 - 21748609

AN - SCOPUS:79960303510

VL - 41

SP - 935

EP - 940

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 7

ER -